BCD-100 - first russian PD-1 inhibitor

BCD-100 - first russian PD-1 inhibitor

Purpose. To evaluate pharmacokinetics, pharmacodynamics, safety, immunogenicity and efficacy of intravenous infusions of BCD-100 (JSC “BIOCAD”, Russia) in increasing doses. Patients (materials) and methods. Patients with advanced malignant tumors of various localizations without severe somatic patho...

Full description

Bibliographic Details
Main Authors: S A Tyulyandin, M Yu Fedyanin, T Yu Semiglazova, V M Moiseenko, S V Odintsova, B Ya Alekseev, R A Ivanov, M S Shustova
Format: Article
Language:Russian
Published: IP Habib O.N. 2017-09-01
Series:Современная онкология
Subjects:
bcd-100
pd-1
oncological diseases
immunotherapy
monoclonal antibody
pharmacokinetics
pharmacodynamics
safety
efficacy
immunogenicity
dose-limiting toxicity
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/27133/pdf

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/27133/pdf

Similar Items